PBYI — Puma Biotechnology Inc

Is PBYI overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Neutral As of October 3, 2026

Puma Biotechnology Inc (PBYI) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $9.51. The rating moved from Overbought to Neutral on October 2, 2026.

Public ratingNeutral (as of October 3, 2026)
Last close$9.51
Last changeMoved from Overbought to Neutral on October 2, 2026
SectorHealthcare
IndustryBiotechnology

AI analysis

Puma Biotechnology combines a pipeline-driven valuation with meaningful binary outcomes tied to clinical and regulatory catalysts. Near-term trading is likely to be choppy given a broader risk-off market tone, sector policy pressure on drug pricing, and typical small-cap biotech liquidity constraints. The company’s funding position and the timing/quality of upcoming data or partnership announcements will be the principal determinants of directional performance over the next month.

Key factors

Clinical-stage pipeline and any near-term data readouts drive binary upside or downside for valuation
Sector-wide investor focus on late-stage biologics lends selective support when asset-specific data/insider conviction is visible
Macroeconomic risk-off tone and light volumes are suppressing near-term upside for small-cap biotech names
Ongoing policy and payer pressure (Medicare negotiation/IRA) increases pricing uncertainty for higher-cost therapies
Company cash runway and ability to fund operations or secure partnerships will determine dilution and near-term financing risk
Competitive dynamics in therapeutic categories (increased combo/GLP-1 innovation where relevant) may pressure market share and pricing

Risks

Clinical trial failure or regulatory setback on key program(s) leading to sharp share price declines
Insufficient cash runway or inability to raise non-dilutive capital, forcing dilutive equity raises at depressed prices
Downward pricing pressure from Medicare negotiation or PBM formulary decisions limiting revenue potential
Intensifying competition from larger pharma (combo GLP-1/amylin entrants or other specialty biologics) eroding addressable market
Low daily liquidity and heightened volatility amplifying downside in risk-off market windows
Manufacturing, supply-chain or commercial execution issues that impair product launches or reorder rates
Negative investor sentiment driven by broader healthcare IPO cooling and reduced speculative capital flows

Latest MarketMoodz coverage

Adidas trims 2026 profit outlook as tariffs bite; Nike and Puma turnarounds2026-03-04
Swiss Re pops 5% on record profit, plans $1.5B buyback2026-02-27
Puma narrows 2025 loss, signals transition year for 20262026-02-26

See today's live rating, score and targets

Members see the live hourly rating for PBYI — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.